The IGF system in patients with type 2 diabetes: associations with markers of cardiovascular target organ damage

• Published in: European journal of endocrinology Vol. 176; no. 5; pp. 521 - 531
• Main Authors: Hjortebjerg, Rikke, Laugesen, Esben, Høyem, Pernille, Oxvig, Claus, Stausbøl-Grøn, Brian, Knudsen, Søren T, Kim, Won Y, Poulsen, Per L, Hansen, Troels K, Bjerre, Mette, Frystyk, Jan
• Format: Journal Article
• Language: English
• Published: England Bioscientifica Ltd 01.05.2017; Oxford University Press
• Subjects: Aged; Biomarkers - blood; Cardiovascular diseases; Cardiovascular Diseases - blood; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - epidemiology; Carotid arteries; Carotid artery; Clinical Study; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - epidemiology; Female; Femur; Humans; Insulin; Insulin-Like Growth Factor Binding Protein 1 - blood; Insulin-Like Growth Factor Binding Protein 2 - blood; Insulin-Like Growth Factor Binding Protein 3 - blood; Insulin-Like Growth Factor Binding Protein 4 - blood; Insulin-like growth factor I; Insulin-Like Growth Factor I - metabolism; Insulin-like growth factor-binding protein 1; Insulin-like growth factor-binding protein 2; Insulin-like growth factor-binding protein 3; Insulin-like growth factor-binding protein 4; Insulin-like growth factors; Magnetic resonance imaging; Male; Metformin; Middle Aged; Multivariate analysis; Pregnancy; Risk factors; Substantia alba
• ISSN: 0804-4643; 1479-683X; 1479-683X
• DOI: 10.1530/EJE-16-0940

Objective Perturbations in the insulin-like growth factor (IGF) system may contribute to the accelerated cardiovascular disease (CVD) that occurs in patients with type 2 diabetes (T2D). However, it remains unknown whether the IGF system is also involved in the development of early, subclinical CVD. We characterised the IGF system in T2D patients and matched controls and examined the associations with markers of subclinical target organ damage. Methods The study included 99 patients with recently diagnosed T2D and 99 age- and sex-matched controls. IGF-1 and IGFBP-1 to -4 were measured by immunoassays, as were pregnancy-associated plasma protein-A (PAPP-A) and the PAPP-A-generated N-terminal (NT) and C-terminal (CT) IGFBP-4 fragments, which are novel CVD risk markers. Arterial stiffness was evaluated by carotid-femoral pulse wave velocity (PWV). Cerebral white matter lesions (WMLs) and carotid artery remodelling were determined by MRI. Results After multivariate adjustments, patients with T2D had lower concentrations of IGFBP-2, IGFBP-4, NT- and CT-IGFBP-4, when compared with controls. IGFBP-2 was inversely correlated to PWV in all subjects in multivariate analysis (P < 0.05), and IGFBP-3 was inversely associated with severity of WMLs (P < 0.05). The NT-IGFBP-4 fragment was associated with the degree of carotid artery remodelling among all subjects (regression coefficient (95% CI): 2.95 (0.70, 5.16), P = 0.011). Levels of NT- and CT-IGFBP-4 were reduced in T2D patients receiving metformin compared to those in controls and patients not receiving metformin. Conclusions Even in recently diagnosed and well-controlled T2D patients, IGF protein levels are altered and associated with CVD risk factors.